following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
.
.
alan knowles, managing director of cura financial services, said: “scottish widows are delivering on their word to customers by paying the majority of the claims they see.
.
.
.
.